New Weight-Loss Drugs Could Well Be America's Next Health Care Disaster
Continued from previous page
In fact, testimony about Qsymia in 2010, when it was first considered, confirmed the problem. Erin Aycock, an obesity patient who spoke during the open-microphone portion of FDA hearings, told the advisory committee that Qsymia was "like instant willpower," and that she "had the ability for the first time in my life to say 'I don't even care if I eat that cookie.'" But that was the good news. Aycock also added that 90 percent of the weight she had lost on Qsymia quickly returned when she quit the drug.